mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2020-2-123-130mrj-1020Research ArticleОБЗОРЫREVIEWSМесто нестероидных противовоспалительных препаратов в современных рекомендациях по остеоартритуThe place of nonsteroidal anti-inflammatory drugs in the current osteoarthritis guidelinesТаскинаЕ. А.TaskinaE. A.

Елена Александровна Таскина

115522, Москва, Каширское шоссе, 34А

Elena Aleksandrovna Taskina

34A, Kashirskoe Shosse, Moscow 115522

braell@mail.ruКашевароваН. Г.KashevarovaN. G.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

АлексееваЛ. И.AlekseevaL. I.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202030052020142123130Copyright © Таскина Е.А., Кашеварова Н.Г., Алексеева Л.И., 20202020Таскина Е.А., Кашеварова Н.Г., Алексеева Л.И.Taskina E.A., Kashevarova N.G., Alekseeva L.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1020

В статье представлен обзор данных литературы, посвященный взаимосвязи боли и риска прогрессирования ОА. В сетевых анализах и многочисленных исследованиях, в том числе проведенных в ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», подтверждено, что болевой синдром является одним из значимых предикторов прогрессирования ОА коленных суставов. К основному классу лекарственных средств для контроля боли при ОА относятся нестероидные противовоспалительные препараты (НПВП). Приведены данные об эффективности у пациентов с ОА мелоксикама, который широко применяется как в России, так и в других странах мира. Мелоксикам характеризуется хорошим профилем безопасности со стороны желудочно-кишечного тракта, сердечно-сосудистой и ренальной систем. Он является препаратом выбора у пациентов с заболеваниями костно-мышечной системы, в частности с ОА. При наличии выраженного болевого синдрома хорошо зарекомендовала себя ступенчатая схема назначения препарата, когда в первые дни лечения применяется инъекционная форма, а затем для закрепления терапевтического успеха – пероральная с учетом сопутствующих заболеваний.

The paper provides a review of the data available in the literature on the relationship of pain to the risk of OA progression. Network analyses and numerous studies, including those conducted at the V.A. Nasonova Research Institute of Rheumatology, have confirmed that pain syndrome is one of the significant predictors of knee OA progression. The major class of medications for OA pain includes nonsteroidal anti-inflammatory drugs. The paper gives data on the efficacy of meloxicam in OA patients, which is widely used in both Russia and other countries of the world. Meloxicam is characterized by a good safety profile in the gastrointestinal tract, cardiovascular and renal systems. It is the drug of choice in patients with musculoskeletal diseases, in particular OA. Good results in severe pain syndrome have been shown by a step-by-step regimen of meloxicam when the injection formulation of the drug is used in the first days of treatment, and then, to consolidate what has been gained from therapy, its oral dosage form is administered in terms of concomitant diseases.

остеоартритболевой синдромпрогрессирование заболеваниярекомендации по остеоартритунестероидные противовоспалительные препаратымелоксикамosteoarthritispain syndromedisease progressionosteoarthritis guidelinesnonsteroidal anti-inflammatory drugsmeloxicamСтатья спонсируется компанией «Берингер Ингельхайм». Спонсор участвовал в разработке проекта исследования и поддержке исследовательской программы, а также принятии решения о представлении статьи для публикации.This article has been supported by Boehringer Ingelhaim. The sponsor has participated in the development of the investigation project and supported the investigation program, as well as in the decision to submit the article for publication.ReferencesDisease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7Балабанова РМ, Дубинина ТВ. Динамика пятилетней заболеваемости болезнями костно-мышечной системы и их распространенности среди взрослого населения России за 2013–2017 гг. Современная ревматология. 2019;13(4):11-7. doi: 10.14412/1996-7012-20194-11-17Balabanova RM, Dubinina TV. Five-year (2013–2017) trends in the incidence and prevalence of musculoskeletal system diseases among the adult population of Russia. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(4):11-7. (In Russ.). doi: 10.14412/1996-7012-20194-11-17Галушко ЕА, Большакова ТВ, Виноградова ИБ и др. Структура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования (предварительные результаты). Научно-практическая ревматология. 2009;47(1):11-7. doi: 10.14412/1995-4484-2009-136Galushko EA, Bol'shakova TV, Vinogradova IB, et al. Structure of rheumatic diseases among adult population of Russia according to data of an epidemiological study (preliminary results). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;47(1):11-7. (In Russ.). doi: 10.14412/1995-4484-2009-136Wilkie R, Parmar SS, Blagojevic-Bucknall M, et al. Reasons why osteoarthritis predicts mortality: path analysis within a cox proportional hazards model. RMD Open. 2019 Nov 13;5(2):e001048. doi: 10.1136/rmdopen2019-001048. eCollection 2019.Wilkie R, Parmar SS, Blagojevic-Bucknall M, et al. Reasons why osteoarthritis predicts mortality: path analysis within a cox proportional hazards model. RMD Open. 2019 Nov 13;5(2):e001048. doi: 10.1136/rmdopen2019-001048. eCollection 2019.Smith D, Wilkie R, Croft P, McBeth J. Pain and Mortality in Older Adults: The Influence of Pain Phenotype. Arthritis Care Res (Hoboken). 2018 Feb;70(2):236-43. doi: 10.1002/acr.23268Smith D, Wilkie R, Croft P, McBeth J. Pain and Mortality in Older Adults: The Influence of Pain Phenotype. Arthritis Care Res (Hoboken). 2018 Feb;70(2):236-43. doi: 10.1002/acr.23268Guillemin F, Ricatte C, Barcenilla-Wong A, et al. Developing a Preliminary Definition and Domains of Flare in Knee and Hip Osteoarthritis (OA): Consensus Building of the Flare-in-OA OMERACT Group. J Rheumatol. 2019 Sep;46(9):1188-91. doi: 10.3899/jrheum.181085. Epub 2019 May 15.Guillemin F, Ricatte C, Barcenilla-Wong A, et al. Developing a Preliminary Definition and Domains of Flare in Knee and Hip Osteoarthritis (OA): Consensus Building of the Flare-in-OA OMERACT Group. J Rheumatol. 2019 Sep;46(9):1188-91. doi: 10.3899/jrheum.181085. Epub 2019 May 15.Parry E, Ogollah R, Peat G. 'Acute flareups' in patients with, or at high risk of, knee osteoarthritis: a daily diary study with casecrossover analysis. Osteoarthritis Cartilage. 2019 Aug;27(8):1124-8. doi: 10.1016/j.joca.2019.04.003Parry E, Ogollah R, Peat G. 'Acute flareups' in patients with, or at high risk of, knee osteoarthritis: a daily diary study with casecrossover analysis. Osteoarthritis Cartilage. 2019 Aug;27(8):1124-8. doi: 10.1016/j.joca.2019.04.003Wang Y, Teichtahl AJ, Abram F, et al. Knee pain as a predictor of structural progression over 4 years: data from the Osteoarthritis Initiative, a prospective cohort study. Arthritis Res Ther. 2018 Nov 6;20(1):250. doi: 10.1186/s13075-018-1751-4Wang Y, Teichtahl AJ, Abram F, et al. Knee pain as a predictor of structural progression over 4 years: data from the Osteoarthritis Initiative, a prospective cohort study. Arthritis Res Ther. 2018 Nov 6;20(1):250. doi: 10.1186/s13075-018-1751-4Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum. 2004 Feb;50(2):476-87.Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum. 2004 Feb;50(2):476-87.Wluka AE, Wolfe R, Stuckey S, Cicuttini FM. How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis? Ann Rheum Dis. 2004 Mar; 63(3):264-8.Wluka AE, Wolfe R, Stuckey S, Cicuttini FM. How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis? Ann Rheum Dis. 2004 Mar; 63(3):264-8.Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther. 2006;8(1):R21. Epub 2005 Dec 30.Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther. 2006;8(1):R21. Epub 2005 Dec 30.Pelletier JP, Raynauld JP, Berthiaume MJ, et al. Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study. Arthritis Res Ther. 2007;9(4):R74.Pelletier JP, Raynauld JP, Berthiaume MJ, et al. Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study. Arthritis Res Ther. 2007;9(4):R74.Eckstein F, Cotofana S, Wirth W, et al. Greater rates of cartilage loss in painful knees than in pain-free knees after adjustment for radiographic disease stage: data from the osteoarthritis initiative. Arthritis Rheum. 2011 Aug;63(8):2257-67. doi: 10.1002/art.30414Eckstein F, Cotofana S, Wirth W, et al. Greater rates of cartilage loss in painful knees than in pain-free knees after adjustment for radiographic disease stage: data from the osteoarthritis initiative. Arthritis Rheum. 2011 Aug;63(8):2257-67. doi: 10.1002/art.30414Saunders J, Ding C, Cicuttini F, Jones G. Radiographic osteoarthritis and pain are independent predictors of knee cartilage loss: a prospective study. Intern Med J. 2012 Mar; 42(3):274-80. doi: 10.1111/j.1445-5994.2011.02438.xSaunders J, Ding C, Cicuttini F, Jones G. Radiographic osteoarthritis and pain are independent predictors of knee cartilage loss: a prospective study. Intern Med J. 2012 Mar; 42(3):274-80. doi: 10.1111/j.1445-5994.2011.02438.xDieppe P, Cushnaghan J, Young P, Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis. 1993 Aug;52(8):557-63.Dieppe P, Cushnaghan J, Young P, Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis. 1993 Aug;52(8):557-63.Cooper C, Snow S, McAlindon TE, et al. Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum. 2000 May;43(5):995-1000.Cooper C, Snow S, McAlindon TE, et al. Risk factors for the incidence and progression of radiographic knee osteoarthritis. Arthritis Rheum. 2000 May;43(5):995-1000.Mazzuca SA, Brandt KD, Schauwecker DS, et al. Severity of joint pain and KellgrenLawrence grade at baseline are better predictors of joint space narrowing than bone scintigraphy in obese women with knee osteoarthritis. J Rheumatol. 2005 Aug;32(8): 1540-6.Mazzuca SA, Brandt KD, Schauwecker DS, et al. Severity of joint pain and KellgrenLawrence grade at baseline are better predictors of joint space narrowing than bone scintigraphy in obese women with knee osteoarthritis. J Rheumatol. 2005 Aug;32(8): 1540-6.Conaghan PG, D'Agostino MA, Le Bars M, et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis. 2010 Apr; 69(4):644-7. doi: 10.1136/ard.2008.099564. Epub 2009 May 10.Conaghan PG, D'Agostino MA, Le Bars M, et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis. 2010 Apr; 69(4):644-7. doi: 10.1136/ard.2008.099564. Epub 2009 May 10.Muraki S, Akune T, Oka H, et al. Incidence and risk factors for radiographic knee osteoarthritis and knee pain in Japanese men and women: a longitudinal populationbased cohort study. Arthritis Rheum. 2012 May; 64(5):1447-56. doi: 10.1002/art.33508Muraki S, Akune T, Oka H, et al. Incidence and risk factors for radiographic knee osteoarthritis and knee pain in Japanese men and women: a longitudinal populationbased cohort study. Arthritis Rheum. 2012 May; 64(5):1447-56. doi: 10.1002/art.33508Driban JB, Price LL, Eaton CB, et al. Individuals with incident accelerated knee osteoarthritis have greater pain than those with common knee osteoarthritis progression: data from the Osteoarthritis Initiative. Clin Rheumatol. 2016 Jun;35(6):1565-71. doi: 10.1007/s10067-015-3128-2. Epub 2015 Nov 27.Driban JB, Price LL, Eaton CB, et al. Individuals with incident accelerated knee osteoarthritis have greater pain than those with common knee osteoarthritis progression: data from the Osteoarthritis Initiative. Clin Rheumatol. 2016 Jun;35(6):1565-71. doi: 10.1007/s10067-015-3128-2. Epub 2015 Nov 27.Bastick AN, Belo JN, Runhaar J, Bierma-Zeinstra SM. What Are the Prognostic Factors for Radiographic Progression of Knee Osteoarthritis? A Metaanalysis. Clin Orthop Relat Res. 2015 Sep;473(9): 2969-89. doi: 10.1007/s11999-015-4349-z. Epub 2015 May 21.Bastick AN, Belo JN, Runhaar J, Bierma-Zeinstra SM. What Are the Prognostic Factors for Radiographic Progression of Knee Osteoarthritis? A Metaanalysis. Clin Orthop Relat Res. 2015 Sep;473(9): 2969-89. doi: 10.1007/s11999-015-4349-z. Epub 2015 May 21.Bastick AN, Runhaar J, Belo JN, Bierma-Zeinstra SM. Prognostic factors for progression of clinical osteoarthritis of the knee: a systematic review of observational studies. Arthritis Res Ther. 2015 Jun 8;17:152. doi: 10.1186/s13075-015-0670-xBastick AN, Runhaar J, Belo JN, Bierma-Zeinstra SM. Prognostic factors for progression of clinical osteoarthritis of the knee: a systematic review of observational studies. Arthritis Res Ther. 2015 Jun 8;17:152. doi: 10.1186/s13075-015-0670-xКашеварова НГ, Алексеева ЛИ, Таскина ЕА, Смирнов АВ. Ведущие факторы прогрессирования остеоартрита коленных суставов. Влияние симптоматических препаратов замедленного действия на течение заболевания (5-летнее проспективное исследование). Фарматека. 2017;(7):40-5.Kashevarova NG, Alekseeva LI, Taskina EA, Smirnov AV. Leading factors in the progression of osteoarthritis of the knee joints. Effect of delayed-acting symptomatic drugs on the course of the disease (5-year prospective study). Farmateka. 2017;(7):40-5. (In Russ.).Алексеева ЛИ, Таскина ЕА, Кашеварова НГ. Остеоартрит: эпидемиология, классификация, факторы риска и прогрессирования, клиника, диагностика, лечение. Современная ревматология. 2019;13(2):9-21. doi: 10.14412/1996-7012-2019-2-9-21Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(2):9-21. (In Russ.). doi: 10.14412/1996-7012-2019-2-9-21Каратеев АЕ. Терапевтический потенциал эторикоксиба в клинической практике. Современная ревматология. 2020; 14(1):108-17. doi: 10.14412/1996-7012-2020-1-108-117.Karateev AE. The therapeutic potential of etoricoxib in clinical practice. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(1):108-17. (In Russ.). doi: 10.14412/1996-7012-2020-1-108-117.Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheum. 2020 Feb; 72(2):220-33. doi: 10.1002/art.41142. Epub 2020 Jan 6.Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheum. 2020 Feb; 72(2):220-33. doi: 10.1002/art.41142. Epub 2020 Jan 6.Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578-89. doi: 10.1016/j.joca.2019.06.011.Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578-89. doi: 10.1016/j.joca.2019.06.011.Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56(Прил. 1):1-29. doi: 10.14412/1995-4484-2018-1-29Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(1S):1-29. (In Russ.). doi: 10.14412/1995-4484-2018-1-29Bhala N, Emberson J, Merhi A, et al. Coxib and traditional NSAID Trialists' (CNT) Collaboration, Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9Bhala N, Emberson J, Merhi A, et al. Coxib and traditional NSAID Trialists' (CNT) Collaboration, Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9Bally M, Beauchamp ME, Abrahamowicz M, et al. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure. Pharmacoepidemiol Drug Saf. 2018;27(1): 69-77. doi: 10.1002/pds.4358Bally M, Beauchamp ME, Abrahamowicz M, et al. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure. Pharmacoepidemiol Drug Saf. 2018;27(1): 69-77. doi: 10.1002/pds.4358Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Apr 30. pii:S0049-0172(19)30043-5. doi: 10.1016/j.semarthrit.2019.04.008Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Apr 30. pii:S0049-0172(19)30043-5. doi: 10.1016/j.semarthrit.2019.04.008Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017 Aug 1;18(1):256. doi: 10.1186/s12882-0170673-8Zhang X, Donnan PT, Bell S, Guthrie B. Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2017 Aug 1;18(1):256. doi: 10.1186/s12882-0170673-8Tsai HJ, Hsu YH, Huang YW, et al. Use of non-steroidal anti-inflammatory drugs and risk of chronic kidney disease in people with Type 2 diabetes mellitus, a nationwide longitudinal cohort study. Diabet Med. 2015 Mar;32(3):382-90. doi: 10.1111/dme.12610Tsai HJ, Hsu YH, Huang YW, et al. Use of non-steroidal anti-inflammatory drugs and risk of chronic kidney disease in people with Type 2 diabetes mellitus, a nationwide longitudinal cohort study. Diabet Med. 2015 Mar;32(3):382-90. doi: 10.1111/dme.12610Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal AntiInflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015 Sep;66(3): 524-33. doi: 10.1161/hypertensionaha.114.05105Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal AntiInflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015 Sep;66(3): 524-33. doi: 10.1161/hypertensionaha.114.05105Зонова ЕВ, Каратеев АЕ. Обоснованный подход к выбору нестероидных противовоспалительных препаратов при остеоартрите. Современная ревматология. 2018;12(4):47-53. doi: 10.14412/1996-7012-2018-4-47-53Zonova EV, Karateev AE. A sound approach to choosing nonsteroidal anti-inflammatory drugs for osteoarthritis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2018;12(4):47-53. (In Russ.). doi: 10.14412/1996-7012-2018-4-47-53https://www.ncbi.nlm.nih.gov/books/NBK548278/https://www.ncbi.nlm.nih.gov/books/NBK548278/Degner F, Türck D, Pairet M. Pharmacological, pharmacokinetic and clinical profile of meloxicam. Drugs Today. 1997;33:739.Degner F, Türck D, Pairet M. Pharmacological, pharmacokinetic and clinical profile of meloxicam. Drugs Today. 1997;33:739.Del Tacca M, Colucci R, Fornai M, et al. Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug. Clin Drug Investig. 2002;22:799.Del Tacca M, Colucci R, Fornai M, et al. Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug. Clin Drug Investig. 2002;22:799.Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11):1-278, iii.Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008 Apr;12(11):1-278, iii.Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life. 2014 Dec; 66(12):803-11. doi: 10.1002/iub.1334. Epub 2014 Dec 23.Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life. 2014 Dec; 66(12):803-11. doi: 10.1002/iub.1334. Epub 2014 Dec 23.Davies NM, Skjodt NM. Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet. 1999 Feb; 36(2):115-26. doi: 10.2165/00003088199936020-00003Davies NM, Skjodt NM. Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet. 1999 Feb; 36(2):115-26. doi: 10.2165/00003088199936020-00003Hawkey C, Kahan A, Steinbrü ck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol. 1998 Sep;37(9):937-45. doi: 10.1093/rheumatology/37.9.937Hawkey C, Kahan A, Steinbrü ck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol. 1998 Sep;37(9):937-45. doi: 10.1093/rheumatology/37.9.937Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Largescale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998 Sep;37(9):946-51.Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Largescale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998 Sep;37(9):946-51.Schoenfeld P. Gastrointestinal safety of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med. 1999 Dec 13;107(6A):48S-54S.Schoenfeld P. Gastrointestinal safety of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med. 1999 Dec 13;107(6A):48S-54S.Asghar W, Jamali F. The effect of COX-2selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015 Feb;23(1):1-16. doi: 10.1007/s10787-014-0225-9Asghar W, Jamali F. The effect of COX-2selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015 Feb;23(1):1-16. doi: 10.1007/s10787-014-0225-9Dalal D, Dubreuil M, Peloquin C, et al. Meloxicam and risk of myocardial infarction: a population-based nested case-control study. Rheumatol Int. 2017 Dec;37(12):2071-8. doi: 10.1007/s00296-017-3835-xDalal D, Dubreuil M, Peloquin C, et al. Meloxicam and risk of myocardial infarction: a population-based nested case-control study. Rheumatol Int. 2017 Dec;37(12):2071-8. doi: 10.1007/s00296-017-3835-xShau WY, Chen HC, Chen ST, et al. Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord. 2012 Feb 2;12:4. doi: 10.1186/1471-2261-12-4Shau WY, Chen HC, Chen ST, et al. Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence. BMC Cardiovasc Disord. 2012 Feb 2;12:4. doi: 10.1186/1471-2261-12-4Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857Lee T, Lu N, Felson DT, et al. Use of non-steroidal anti-inflammatory drugs correlates withthe risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study. Rheumatology (Oxford). 2016 Jun;55(6):1099-105. doi: 10.1093/rheumatology/kew036Lee T, Lu N, Felson DT, et al. Use of non-steroidal anti-inflammatory drugs correlates withthe risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study. Rheumatology (Oxford). 2016 Jun;55(6):1099-105. doi: 10.1093/rheumatology/kew036Jung SY, Jang EJ, Nam SW, et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol. 2018 Nov;28(6):1021-8. doi: 10.1080/14397595.2018.1439694Jung SY, Jang EJ, Nam SW, et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol. 2018 Nov;28(6):1021-8. doi: 10.1080/14397595.2018.1439694Алексеев ВВ. Боль в поясничном отделе позвоночника: диагностика и лечение. Трудный пациент. 2004;2(4):1-8.Alekseev VV. Lumbar spine pain: diagnosis and treatment. Trudnyi patsient. 2004;2(4): 1-8. (In Russ.).Цветкова ЕС. Эффективность и переносимость ступенчатой терапии мовалисом (мелоксикамом) при ревматических заболеваниях. Терапевтический архив. 2004;(12):78-80.Tsvetkova ES. Effectiveness and tolerability of step therapy with Movalis (meloxicam) in rheumatic diseases. Terapevticheskii arkhiv. 2004;(12):78-80. (In Russ.).Алексеева ЛИ, Кашеварова НГ, Торопцова НВ, Никитинская ОА. Оценка эффективности и переносимости «ступенчатой» терапии мовалисом у больных с синдромом боли в нижней части спины, сочетающимся с остеоартрозом и остеопорозом. Научно-практическая ревматология. 2005;43(6):53-5.Alekseeva LI, Kashevarova NG, Toroptsova NV, Nikitinskaya OA. Evaluation of the effectiveness and tolerability of «step» therapy with Movalis in patients with lower back pain syndrome, combined with osteoarthritis and osteoporosis. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2005;43(6):53-5. (In Russ.).

The authors declare that there are no conflicts of interest present.